Hyperglycemia secondary to megestrol acetate for endometrial neoplasia.
Two patients with endometrial neoplasia developed severe hyperglycemia secondary to megestrol acetate. Patients who receive progestational therapy with megestrol acetate for endometrial neoplasia should be monitored closely for potentially severe hyperglycemia, especially if they have a history of abnormal glucose metabolism.
Rose
P G
PG
Department of Obstetrics and Gynecology, University MacDonald Womens Hospital, Case Western Reserve University, Cleveland, Ohio 44106, USA.
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000473:pathology; D000236:Adenoma / Q000188:drug therapy* / Q000473:pathology; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D004714:Endometrial Hyperplasia / Q000188:drug therapy / Q000473:pathology; D016889:Endometrial Neoplasms / Q000188:drug therapy*; D005260:Female; D006801:Humans; D006943:Hyperglycemia / Q000139:chemically induced* / Q000188:drug therapy; D007328:Insulin / Q000627:therapeutic use; D008535:Megestrol / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D019290:Megestrol Acetate; D008875:Middle Aged
D000970:Antineoplastic Agents; D007328:Insulin; D008535:Megestrol; D019290:Megestrol Acetate